PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19724024-0	2009	Rosuvastatin attenuates Ang II--mediated cardiomyocyte hypertrophy via inhibition of LOX-1.	Rosuvastatin Calcium	0-12	oxidized low density lipoprotein (lectin-like) receptor 1	Mus musculus	85-90	
19724024-9	2009	Rosuvastatin also reduced Ang II-mediated upregulation of AT1R and LOX-1.	Rosuvastatin Calcium	0-12	oxidized low density lipoprotein (lectin-like) receptor 1	Mus musculus	67-72	
19724024-10	2009	In other experiments, LOX-1 was upregulated in cardiomyocytes by transfection with pCI-neo/LOX-1, which also enhanced the expression AT1R messenger RNA (mRNA), and rosuvastatin pretreatment reduced the expression of both LOX-1 and AT1R in this system.	Rosuvastatin Calcium	164-176	oxidized low density lipoprotein (lectin-like) receptor 1	Mus musculus	22-27	
19724024-10	2009	In other experiments, LOX-1 was upregulated in cardiomyocytes by transfection with pCI-neo/LOX-1, which also enhanced the expression AT1R messenger RNA (mRNA), and rosuvastatin pretreatment reduced the expression of both LOX-1 and AT1R in this system.	Rosuvastatin Calcium	164-176	oxidized low density lipoprotein (lectin-like) receptor 1	Mus musculus	91-96	
19724024-10	2009	In other experiments, LOX-1 was upregulated in cardiomyocytes by transfection with pCI-neo/LOX-1, which also enhanced the expression AT1R messenger RNA (mRNA), and rosuvastatin pretreatment reduced the expression of both LOX-1 and AT1R in this system.	Rosuvastatin Calcium	164-176	oxidized low density lipoprotein (lectin-like) receptor 1	Mus musculus	91-96	
19724024-11	2009	Thus, rosuvastatin attenuates Ang II-mediated cardiomyocyte growth by inhibiting LOX-1 and AT1R expression and suppressing the heightened intracellular redox state.	Rosuvastatin Calcium	6-18	oxidized low density lipoprotein (lectin-like) receptor 1	Mus musculus	81-86	
19724024-3	2009	We postulated that rosuvastatin, a potent HMG-CoA reductase inhibitor, may reduce Ang II-mediated cardiomyocyte growth via AT1R and LOX-1 inhibition.	Rosuvastatin Calcium	19-31	oxidized low density lipoprotein (lectin-like) receptor 1	Mus musculus	132-137	
16005008-10	2006	While rosuvastatin and candesartan each had a small inhibitory effect on the expression of LOX-1 in the atherosclerotic tissues, the combination totally blocked the up-regulation of LOX-1.	Rosuvastatin Calcium	6-18	oxidized low density lipoprotein (lectin-like) receptor 1	Mus musculus	91-96	
19687748-8	2009	Administration of rosuvastatin or amlodipine reduced the overexpression of genes for LOX-1 and AT1R and associated NADPH oxidase and NF-kappaB.	Rosuvastatin Calcium	18-30	oxidized low density lipoprotein (lectin-like) receptor 1	Mus musculus	85-90	
33093907-9	2020	Furthermore, sarpogrelate combined with rosuvastatin treatment significantly decreased the expression levels of LOX-1 and p-ERK.	Rosuvastatin Calcium	40-52	oxidized low density lipoprotein (lectin-like) receptor 1	Mus musculus	112-117	
33093907-10	2020	Taken together, these results suggest that the positive effects of sarpogrelate combined with rosuvastatin treatment on aortic injury may be associated with the regulation of the LOX-1/p-ERK signaling pathway.	Rosuvastatin Calcium	94-106	oxidized low density lipoprotein (lectin-like) receptor 1	Mus musculus	179-184	
33029491-8	2020	The analysis of expression profiles at both the RNA and protein levels, using real-time quantitative polymerase chain reaction and Western blot analysis, indicated that LDL-R/CD68/LOX-1-positive monocyte/macrophage-mediated enhanced proinflammatory activation, including the significant upregulation of tumor necrosis factor-alpha and interleukin-6, was actually attenuated by sarpogrelate and/or rosuvastatin treatment.	Rosuvastatin Calcium	397-409	oxidized low density lipoprotein (lectin-like) receptor 1	Mus musculus	180-185